Antibody therapeutics are a dominating feature of the current drug development landscape, but increasing costs and time-consuming workflows represent major barriers to their discovery and development.

Single-cell RNA-seq (scRNA-seq) has spent the past decade maturing into a foundational technology. Over that time, the technology has both laid the foundation for building cell atlases and allowed ...